EUVIMEDEUVIMED entdecken
Crossref

Efficacy of adjuvant intralesional rituximab in patients with pemphigus vulgaris and oral lesions receiving systemic rituximab: A randomized controlled pilot trial

Fahimeh Firouz, Faeghe Sheikhalizadeh Nobar, Hossein Azizi

Medicina Clínica · 2026-10 · 107662

DOI: 10.1016/j.medcli.2026.107662 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medicina Clínica, 2026-10. Verfasst von Fahimeh Firouz und 2 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Research Development Unit, Sina Education, Research and Treatment Center, Tabriz University of Medical Sciences, Tabriz, Iran. Die Arbeit nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: To evaluate the adjuvant effect of intralesional rituximab added to systemic rituximab therapy in patients with pemphigus vulgaris and active oral lesions. METHODS: In this randomized controlled pilot trial, 20 patients with pemphigus vulgaris and active oral lesions were randomly assigned to receive systemic rituximab alone (control group) or systemic rituximab plus intralesional rituximab (intervention group). In the intervention group, one or two active, non-infected oral lesions were treated with intralesional rituximab (10mg/mL) in two sessions 15days apart. Pain intensity and mucosal disease severity were assessed using the Visual Analog Scale (VAS) and Pemphigus Vulgaris Lesion Severity Score (PVLSS) at baseline, Day 15, Day 30, and three months. RESULTS: At three months, the mean VAS score was significantly lower in the intervention group than in the control group (0.42±0.20 vs. 1.10±0.56; P=.001). The mean PVLSS was also significantly lower in the intervention group (0.20±0.42 vs. 0.70±0.48; P=.024). No significant between-group differences were observed at Day 15 for either outcome. These findings indicate greater improvement in pain and mucosal lesion severity with the addition of intralesional rituximab. CONCLUSION: Adding intralesional rituximab to systemic rituximab therapy may provide additional clinical benefit in patients with pemphigus vulgaris and active oral lesions. Given the pilot nature and small sample size of this study, larger controlled trials are needed to confirm these findings.

Schlagwörter

Stichwörter der Autor:innen

Intralesional therapyLesiones oralesOral lesionsPVLSSPemphigus vulgarisPénfigo vulgarRituximabTratamiento intralesional

Autor:innen und Institutionen

  • Clinical Research Development Unit, Sina Education, Research and Treatment Center, Tabriz University of Medical Sciences, Tabriz, Iran.
  • Clinical Research Development Unit, Sina Education, Research and Treatment Center, Tabriz University of Medical Sciences, Tabriz, Iran. Electronic address: sheikhalizadehf@tbzmed.ac.ir.
  • Clinical Research Development Unit, Sina Education, Research and Treatment Center, Tabriz University of Medical Sciences, Tabriz, Iran; Sarab Faculty of Medical Sciences, Sarab, Iran; Clinical Research Development Unit…

Zitieren

APA

Firouz, F., Sheikhalizadeh Nobar, F., & Azizi, H. (2026). Efficacy of adjuvant intralesional rituximab in patients with pemphigus vulgaris and oral lesions receiving systemic rituximab: A randomized controlled pilot trial. Medicina Clínica, 107662. https://doi.org/10.1016/j.medcli.2026.107662

Vancouver

Firouz F, Sheikhalizadeh Nobar F, Azizi H. Efficacy of adjuvant intralesional rituximab in patients with pemphigus vulgaris and oral lesions receiving systemic rituximab: A randomized controlled pilot trial. Medicina Clínica. 2026:107662. doi:10.1016/j.medcli.2026.107662

BibTeX
@article{Firouz2026,
  author = {Firouz, Fahimeh and Sheikhalizadeh Nobar, Faeghe and Azizi, Hossein},
  title = {Efficacy of adjuvant intralesional rituximab in patients with pemphigus vulgaris and oral lesions receiving systemic rituximab: A randomized controlled pilot trial},
  journal = {Medicina Clínica},
  year = {2026},
  pages = {107662},
  doi = {10.1016/j.medcli.2026.107662}
}
Kostenlos starten →